Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2022 ASH annual meeting

Venetoclax (VEN), the first selective Bcl-2 inhibitor, has shown efficacy and safety both as monotherapy and in combination with other agents in the treatment of newly diagnosed acute myeloid leukemia (AML), while its role in relapsed or refractory (R/R) disease is not well defined. Here, we reviewe...

Descripción completa

Detalles Bibliográficos
Autores principales: Gong, Xubo, Zhang, Yi, He, Xin, Moloudizargari, Milad, Yu, Teng, Wang, Lin, Liu, Weiwei, Jin, Lan, Xu, Huiying, Xu, Yang, Tao, Zhihua, Qian, Wenbin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314591/
https://www.ncbi.nlm.nih.gov/pubmed/37391809
http://dx.doi.org/10.1186/s40164-023-00424-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314591/
https://www.ncbi.nlm.nih.gov/pubmed/37391809
http://dx.doi.org/10.1186/s40164-023-00424-z

Ejemplares similares